1. CAD/PAD in Primary Care

3. CV Risk in Stable Outpatients Stratified by Baseline CV Risk Category

4. Aspirin for Secondary Prevention of CV Disease

5. Anticoagulant Therapy in CAD Warfarin -- WARIS-2

6. ATLAS ACS 2 -- TIMI 51 Rivaroxaban vs Placebo After ACS

7. COMPASS Trial Design

8. COMPASS Primary Efficacy Outcome -- CV Death/MI/Stroke

9. COMPASS Cumulative Risk of CV Death/Stroke/MI

10. COMPASS Bleeding Outcomes

11. COMPASS CV Death and All-Cause Death

12. COMPASS: CAD and PAD Cohorts

13. COMPASS PAD Cohort Peripheral Limb Outcomes

14. Potential Tolerability Concerns With Adding Rivaroxaban Therapy

15. Managing Tolerability Concerns

16. Strategies to Improve Persistence and Adherence to Rivaroxaban Therapy

17. Correct Dose of Rivaroxaban

18. VOYAGER PAD

19. PAD Screening Recommendations

20. Rivaroxaban FDA Approval: October 15, 2018

21. External Applicability of the COMPASS Trial REACH Registry

22. Managing Patients with Stable CAD/PAD in Primary Care

23. Summary

24. Abbreviations

25. Abbreviations (cont)